PE20240816A1 - DERIVADOS DE AMINA BICICLICOS COMO MODULADORES DE RECEPTOR GABAA (alfa)5 - Google Patents

DERIVADOS DE AMINA BICICLICOS COMO MODULADORES DE RECEPTOR GABAA (alfa)5

Info

Publication number
PE20240816A1
PE20240816A1 PE2024000597A PE2024000597A PE20240816A1 PE 20240816 A1 PE20240816 A1 PE 20240816A1 PE 2024000597 A PE2024000597 A PE 2024000597A PE 2024000597 A PE2024000597 A PE 2024000597A PE 20240816 A1 PE20240816 A1 PE 20240816A1
Authority
PE
Peru
Prior art keywords
receptor
compounds
gabaa
alpha5
alpha
Prior art date
Application number
PE2024000597A
Other languages
English (en)
Spanish (es)
Inventor
Imre Bata
Gyorgy Szabo
Attila Potor
Gyorgy Istvan Turos
Oliver Elias
Gabor Laszlo Kapus
Peter Erdelyi
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of PE20240816A1 publication Critical patent/PE20240816A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2024000597A 2021-09-29 2022-09-28 DERIVADOS DE AMINA BICICLICOS COMO MODULADORES DE RECEPTOR GABAA (alfa)5 PE20240816A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP2100338A HU231691B1 (hu) 2021-09-29 2021-09-29 GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok
PCT/IB2022/059214 WO2023053015A1 (en) 2021-09-29 2022-09-28 BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Publications (1)

Publication Number Publication Date
PE20240816A1 true PE20240816A1 (es) 2024-04-18

Family

ID=89993434

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2024000597A PE20240816A1 (es) 2021-09-29 2022-09-28 DERIVADOS DE AMINA BICICLICOS COMO MODULADORES DE RECEPTOR GABAA (alfa)5

Country Status (21)

Country Link
US (1) US20250051323A1 (enExample)
EP (1) EP4408842A1 (enExample)
JP (1) JP2024536039A (enExample)
KR (1) KR20240089056A (enExample)
CN (1) CN118284606A (enExample)
AR (1) AR127182A1 (enExample)
AU (1) AU2022357572A1 (enExample)
CA (1) CA3231776A1 (enExample)
CL (1) CL2024000893A1 (enExample)
CO (1) CO2024005424A2 (enExample)
CU (1) CU20240013A7 (enExample)
EC (1) ECSP24032316A (enExample)
GE (2) GEAP202416510A (enExample)
HU (1) HU231691B1 (enExample)
IL (1) IL311640A (enExample)
JO (1) JOP20240057A1 (enExample)
MX (1) MX2024003812A (enExample)
PE (1) PE20240816A1 (enExample)
TW (1) TW202330518A (enExample)
WO (1) WO2023053015A1 (enExample)
ZA (1) ZA202403230B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024251133A1 (zh) * 2023-06-05 2024-12-12 武汉人福创新药物研发中心有限公司 作为α5-GABAA受体调节剂的杂环化合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU230518B1 (hu) 2005-12-20 2016-10-28 Richter Gedeon Nyrt. Bradykinin B1 receptor szelektív antagonista hatással rendelkező új fenatridin származékok, eljárás előállításukra, és az ezeket tartalmazó gyógyszerkészítmények
HUP0600810A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New sulfonamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
HUP0600808A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New benzamide derivatives as bradykinin antagonists, process for their preparation and pharmaceutical compositions containing them
HUP0600809A3 (en) 2006-10-27 2008-09-29 Richter Gedeon Nyrt New phenylsulfamoyl-benzamide derivatives as bradykinin antagonists, process and intermediates for their preparation and pharmaceutical compositions containing them
US7943619B2 (en) 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US8742097B2 (en) 2010-11-09 2014-06-03 Hoffmann-La Roche Inc. Triazole compounds I
WO2014001279A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
KR20150033679A (ko) 2012-06-26 2015-04-01 사니오나 에이피에스 페닐 트리아졸 유도체 및 이의 gabaa 수용체 복합체 조절용 용도
WO2014001278A1 (en) 2012-06-26 2014-01-03 Aniona Aps A phenyl triazole derivative and its use for modulating the gabaa receptor complex
HUP1300139A2 (en) 2013-03-06 2014-09-29 Richter Gedeon Nyrt Phenoxypiperidine h3 antagonists
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
PT3439665T (pt) 2016-03-18 2022-09-27 Uwm Res Foundation Inc Tratamento de sintomas cognitivos e de humor em distúrbios neurodegenerativos e neuropsiquiátricos com gaba contendo agonistas de recetores de gabaa contendo alfa5
UA125524C2 (uk) 2016-12-08 2022-04-13 Ф. Хоффманн-Ля Рош Аг Ефірні похідні ізоксазолу як позитивні алостеричні модулятори рецептора гамк а альфа-5
HU231058B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt. Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok
HU231057B1 (hu) 2017-03-13 2020-04-28 Richter Gedeon Nyrt Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
TW201938171A (zh) 2017-12-15 2019-10-01 匈牙利商羅特格登公司 作為血管升壓素V1a受體拮抗劑之三環化合物
HU231206B1 (hu) 2017-12-15 2021-10-28 Richter Gedeon Nyrt. Triazolobenzazepinek
AU2019286312B2 (en) 2018-06-13 2023-08-17 F. Hoffmann-La Roche Ag New isoxazolyl ether derivatives as GABA A alpha5 PAM
HU231414B1 (hu) 2018-07-13 2023-08-28 Richter Gedeon Nyrt. Tiadiazin származékok
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
HU231478B1 (hu) 2018-07-13 2024-02-28 Richter Gedeon Nyrt. Szubsztituált (aza)indol származékok
BR102019014802A2 (pt) 2018-07-20 2020-02-04 Boehringer Ingelheim Int difluorometil-fenil triazóis
HU231223B1 (hu) * 2018-09-28 2022-01-28 Richter Gedeon Nyrt. GABAA A5 receptor modulátor hatású biciklusos vegyületek
TWI901650B (zh) * 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物

Also Published As

Publication number Publication date
JP2024536039A (ja) 2024-10-04
TW202330518A (zh) 2023-08-01
WO2023053015A1 (en) 2023-04-06
GEAP202416510A (en) 2024-08-12
CU20240013A7 (es) 2024-11-15
JOP20240057A1 (ar) 2024-03-20
CA3231776A1 (en) 2023-04-06
HUP2100338A1 (hu) 2023-04-28
IL311640A (en) 2024-05-01
GEP20257812B (en) 2025-10-27
MX2024003812A (es) 2024-04-25
CO2024005424A2 (es) 2024-05-10
ECSP24032316A (es) 2024-05-31
ZA202403230B (en) 2024-12-18
KR20240089056A (ko) 2024-06-20
CN118284606A (zh) 2024-07-02
HU231691B1 (hu) 2025-10-28
AR127182A1 (es) 2023-12-27
EP4408842A1 (en) 2024-08-07
CL2024000893A1 (es) 2024-09-06
AU2022357572A1 (en) 2024-05-02
US20250051323A1 (en) 2025-02-13

Similar Documents

Publication Publication Date Title
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
ES2710190T3 (es) Derivados de 4-azaindol
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
AR059328A1 (es) Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp
ES2623777T3 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR080878A1 (es) Derivados heterociclicos de ariletinilo, composiciones farmaceuticas que los contienen, metodo para prepararlos y uso de los mismos en el tratamiento de la esquizofrenia y trastornos cognitivos.
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
AR047098A1 (es) Derivados de arilanilina como agonistas del receptor adrenergico beta2
AR075517A1 (es) Derivados de isoxazol-isoxazol y de isoxazol-isotiazol
AR079467A1 (es) Derivados heterociclicos nitrogenados de etinilo, composiciones farmaceuticas que los contienen, proceso para prepararlos y uso de los mismos para tratar y/o prevenir enfermedades cognitivas o esquizofrenia.
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR076401A1 (es) Bisaril alquinilamidas como moduladores alostericos negativos del receptor metabotropico de glutamato 5 (mglur5)
PE20220704A1 (es) Derivados de 3,6-diamino-piridazin-3-ilo, composiciones farmaceuticas que los contienen y sus usos como agentes proapoptoticos
CL2020001564A1 (es) Triazolobenzazepinas como antagonistas del receptor v1a de la vasopresina.
ECSP22093794A (es) Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos
AR111176A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
AR125367A1 (es) Moduladores alostéricos positivos del receptor muscarínico m1 de acetilcolina
DE60214401D1 (de) Hetero-bicyclische crf antagonisten
PE20231097A1 (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso
AR069286A1 (es) Derivados heterociclicos
AR072802A1 (es) Derivados piperidinicos de esteres de acido bifenil-2-il-carbamico, antagonistas de receptores muscarinicos m3, composiciones farmaceuticas que los contienen y usos de los mismos para el tratamiento de trastornos digestivos,respiratorios y/o urinarios.
PE20240107A1 (es) Derivados de pirazolo[1,5-a]pirimidina sustituidos con heterociclicos farmacologicamente activos
EA202190857A1 (ru) Бициклические производные как модуляторы 5 рецепторов gabaa